Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Gastrointestinal 3Genitourinary 2Dermatologic 2

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma of the Stomach 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × tesetaxel × Gastrointestinal × Clear all
NCT01573468 2012-07-24

TESEGAST

Genta Incorporated

Phase 2 Unknown
580 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00080834 2012-05-16

DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma

Daiichi Sankyo

Phase 2 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01095120 2012-03-15

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Genta Incorporated

Phase 2 Unknown
27 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

Data powered by HemOnc (CC BY 4.0) Colophon âš¡